Literature DB >> 6137813

Thiazides, beta blockers and lipoproteins.

D Ballantyne, F C Ballantyne.   

Abstract

Some of the more important recent studies on the effect of thiazides and beta-adrenoceptor blocking agents is conflicting, possibly because of differences in patient compliance and in lipoprotein methodology and quality assurance between studies. It is likely that in the short-term, thiazide diuretics produce an increase in plasma triglyceride and cholesterol and in LDL-cholesterol. No consistent effect of monotherapy with beta-adrenoceptor blocking agents was seen. Further long-term studies of monotherapy with both of these classes of drugs are required. Combined therapy with thiazides or beta-adrenoceptor blocking agents consistently increased plasma triglyceride concentrations, but their effect on VLDL, LDL and HDL concentrations is uncertain. Further research required into the effect of these drugs on apolipoproteins which may be useful discriminators for patients with coronary heart disease (Avogaro et al., 1979) and on HDL subfractions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137813      PMCID: PMC2417577          DOI: 10.1136/pgmj.59.694.483

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  33 in total

1.  Metabolic effects of beta-adrenoreceptor blockers.

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976       Impact factor: 9.546

2.  Beta-blockers and lipid metabolism.

Authors:  A Nilsson; B G Hansson; B Hökfelt
Journal:  Br Med J       Date:  1977-07-09

3.  High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study.

Authors:  A Helgeland; I Hjermann; P Leren; S Enger; I Holme
Journal:  Br Med J       Date:  1978-08-05

4.  Effect of chronic administration of propranolol on lipoprotein composition.

Authors:  N Tanaka; S Sakaguchi; K Oshige; T Niimura; T Kanehisa
Journal:  Metabolism       Date:  1976-10       Impact factor: 8.694

5.  Relationship of plasma lipids and lipoprotein concentration to cerebral atherosclerosis and electrocardiographic findings.

Authors:  D Ballantyne; K W Grossart; J P Ballantyne; A Young; T D Lawrie
Journal:  J Neurol Sci       Date:  1974-10       Impact factor: 3.181

6.  Propranolol and hypertriglyceridemia.

Authors:  J J Barboriak; H D Friedberg
Journal:  Atherosclerosis       Date:  1973 Jan-Feb       Impact factor: 5.162

7.  Increase in serum-lipids during treatment of hypertension with chlorthalidone.

Authors:  R P Ames; P Hill
Journal:  Lancet       Date:  1976-04-03       Impact factor: 79.321

8.  Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. The Oslo study.

Authors:  A Helgeland; I Hjermann; I Holme; P Leren
Journal:  Am J Med       Date:  1978-01       Impact factor: 4.965

9.  Elevation of serum lipid levels during diuretic therapy of hypertension.

Authors:  R P Ames; P Hill
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

10.  Effects of long-term practolol therapy on plasma-lipids after acute myocardial infarction.

Authors:  P Ghosh; A M Cochrane; D de Bono
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

View more
  5 in total

Review 1.  The effects of treatment on target organ damage in hypertensive disease.

Authors:  J Lowenstein
Journal:  Postgrad Med J       Date:  1985-09       Impact factor: 2.401

2.  Evaluation and treatment of hypercholesterolemia--another step.

Authors:  W E May; B L Baker
Journal:  J Gen Intern Med       Date:  1987 Jan-Feb       Impact factor: 5.128

3.  Beta blockers, lipids, and coronary atherosclerosis.

Authors:  A Ramani; S Nayak; G N Kundaje; A R Aroor
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-30

4.  Beta blockers, lipids, and coronary atherosclerosis: fact or fiction?

Authors:  R J Northcote
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-12

5.  Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension.

Authors:  A Terént; M Ribacke; L A Carlson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.